Back to Oncology
Oncologyv2010Evidence-Based

Modified Response Evaluation Criteria in Solid Tumors (mRECIST)

Assesses treatment response in hepatocellular carcinoma (HCC) patients based on viable tumor enhancement, specifically designed for patients receiving targeted therapies and locoregional treatments.

Clinical Input Parameters

cm
Range: 0.1 — 50 cm
cm
Range: 0 — 50 cm
Clinical Assessment
Awaiting Parameters
mrecist response
—response_category
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Modified Response Evaluation Criteria in Solid Tumors (mRECIST) is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within oncology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

mRECIST Response = f(baseline_sum_diameters, current_sum_diameters, enhancement_status). Complete Response: disappearance of arterial enhancement. Partial Response: ≥30% decrease in viable tumor. Progressive Disease: ≥20% increase in viable tumor or new lesions. Stable Disease: neither PR nor PD criteria.

Clinical Pearls & Practice Notes

  • Target lesions must be ≥1.0 cm in diameter and show intratumoral arterial enhancement on CT or MRI
  • Viable tumor is defined as tissue showing uptake in arterial phase of contrast-enhanced imaging
  • European Association for the Study of the Liver (EASL) guidelines recommend evaluation 1 month after treatment
  • mRECIST is superior to standard RECIST 1.1 for HCC assessment, particularly with antiangiogenic drugs
  • Measurement should be performed on CT or MRI obtained in arterial phase when contrast is highest

Evidence & Literature Citations

  1. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52-60. doi: 10.1055/s-0030-1247132.
  2. Forner A, Ayuso C, Varela M, et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer. 2009;115(3):616-23. doi: 10.1002/cncr.24050.
  3. Edeline J, Boucher E, Rolland Y, et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer. 2012;118(1):147-56. doi: 10.1002/cncr.26255.

Score Interpretation Ranges

Complete Response≤ pts

Disappearance of arterial enhancement

Partial Response≤ pts

≥30% decrease in viable tumor

Stable Disease≤ pts

Neither PR nor PD criteria met

Progressive Disease≤ pts

≥20% increase in viable tumor

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.